TNSN05262A1 - ALPHA-SUBSTITUTED CARBOXYLIC ACIDS AS MODULATORS OF PPAR - Google Patents
ALPHA-SUBSTITUTED CARBOXYLIC ACIDS AS MODULATORS OF PPARInfo
- Publication number
- TNSN05262A1 TNSN05262A1 TNP2005000262A TNSN05262A TNSN05262A1 TN SN05262 A1 TNSN05262 A1 TN SN05262A1 TN P2005000262 A TNP2005000262 A TN P2005000262A TN SN05262 A TNSN05262 A TN SN05262A TN SN05262 A1 TNSN05262 A1 TN SN05262A1
- Authority
- TN
- Tunisia
- Prior art keywords
- alpha
- ppar
- carboxylic acids
- formula
- substituted carboxylic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/14—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Des acides carboxyliques alpha-substitués de formule (1) : Dans laquelle R1 et R2 sont tels que définis dans le présent mémoire et R3 répond à A) la formule (II) ; B) la formule (III) ; C) la formule (IV) ; et D) la formule (V) ; dans lesquelles Y, Y'', Ar1, Ar2, Ar3, Ar4, R4, R5, R6, R7, R8, R9, R9a, R11, R12, R17, le noyau A et p sont tels que définis dans le présent mémoire ; des compositions pharmaceutiques contenant des quantités efficaces desdits composés ou de leurs sels, sont utiles pour le traitement d'affections en rapport avec PPAR, spécifiquement de troubles en rapport avec PPAr alpha/y, tels que le diabète, la dyslipidémie, l'obésité et des troubles inflammatoires.Alpha-substituted carboxylic acids of formula (1): wherein R 1 and R 2 are as defined herein and R 3 is A) (II); B) formula (III); C) formula (IV); and D) formula (V); wherein Y, Y '', Ar1, Ar2, Ar3, Ar4, R4, R5, R6, R7, R8, R9, R9a, R11, R12, R17, ring A and p are as defined herein; pharmaceutical compositions containing effective amounts of said compounds or salts thereof, are useful for the treatment of PPAR-related conditions, specifically of alpha-mediated PPAr disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46321303P | 2003-04-15 | 2003-04-15 | |
PCT/IB2004/001159 WO2004092145A1 (en) | 2003-04-15 | 2004-04-01 | Alpha substituted carboxylic acid as ppar modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN05262A1 true TNSN05262A1 (en) | 2007-07-10 |
Family
ID=33300053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2005000262A TNSN05262A1 (en) | 2003-04-15 | 2005-10-14 | ALPHA-SUBSTITUTED CARBOXYLIC ACIDS AS MODULATORS OF PPAR |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1615899A1 (en) |
JP (1) | JP2006523671A (en) |
KR (1) | KR20060009846A (en) |
CN (1) | CN1805943A (en) |
AP (1) | AP2005003418A0 (en) |
AR (1) | AR044514A1 (en) |
AU (1) | AU2004230316A1 (en) |
BR (1) | BRPI0409429A (en) |
CA (1) | CA2521915A1 (en) |
CL (1) | CL2004000800A1 (en) |
EA (1) | EA200501462A1 (en) |
EC (1) | ECSP056105A (en) |
IS (1) | IS8033A (en) |
MA (1) | MA27764A1 (en) |
MX (1) | MXPA05010967A (en) |
NL (1) | NL1025946C2 (en) |
NO (1) | NO20055370L (en) |
OA (1) | OA13157A (en) |
PA (1) | PA8600201A1 (en) |
PE (1) | PE20050415A1 (en) |
TN (1) | TNSN05262A1 (en) |
TW (1) | TW200510353A (en) |
UY (1) | UY28266A1 (en) |
WO (1) | WO2004092145A1 (en) |
ZA (1) | ZA200508362B (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005247473A1 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Substituted triazoles as modulators of PPAR and methods of their preparation |
CA2607617A1 (en) | 2005-05-09 | 2006-11-16 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
JP5043120B2 (en) | 2006-10-30 | 2012-10-10 | クロマ セラピューティクス リミテッド | Hydroxamates as inhibitors of histone deacetylase |
KR101558005B1 (en) | 2007-03-08 | 2015-10-06 | 알비레오 에이비 | 2--3- 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease |
KR20100020484A (en) | 2007-05-22 | 2010-02-22 | 아칠리온 파르마세우티칼스 인코포레이티드 | Heteroaryl substituted thiazoles and their use as antiviral agents |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
NZ602832A (en) | 2008-07-14 | 2014-04-30 | Gilead Sciences Inc | Fused heterocyclic hdac inhibitor compounds |
US8344018B2 (en) | 2008-07-14 | 2013-01-01 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
JP5640005B2 (en) | 2008-07-14 | 2014-12-10 | ギリアード サイエンシーズ, インコーポレイテッド | Imidazosylpyridine compounds as HDAC and / or CDK inhibitors |
NZ590747A (en) | 2008-07-28 | 2012-11-30 | Gilead Sciences Inc | Cycloalkylidene and heterocycloalkylidene hdac inhibitor compounds |
NZ596863A (en) | 2009-06-08 | 2014-02-28 | Gilead Sciences Inc | Alkanoylamino benzamide aniline hdac inhibitor compounds |
BRPI1010883A2 (en) | 2009-06-08 | 2018-07-10 | Gilead Sciences Inc | aniline cycloalkylcarbamate benzamide hdac inhibiting compounds. |
DE102010055499A1 (en) * | 2010-12-22 | 2011-06-16 | W.C. Heraeus Gmbh | Preparing bendamustine alkyl ester compounds, comprises reacting substituted 2-((2-hydroxy-ethyl)-phenyl-amino)-ethanol compounds with a mixture comprising carbonyl amine compounds and sulfonyl compounds, or diketo compounds |
CA2853439A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
BR112014010368A2 (en) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc | biaryl ether sulfonamides and their use as therapeutic agents |
FR2982858B1 (en) * | 2011-11-18 | 2013-11-29 | Rhodia Operations | PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRIL FUNCTIONS |
FR2984322B1 (en) * | 2011-12-16 | 2013-12-20 | Rhodia Operations | PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRIL FUNCTIONS |
WO2013177224A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
KR101663436B1 (en) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-substituted benzamides and methods of use thereof |
BR112015022488A2 (en) | 2013-03-14 | 2017-07-18 | Genentech Inc | substituted triazolopyridines and methods of use thereof |
CA2898680A1 (en) | 2013-03-15 | 2014-09-18 | Genentech,Inc. | Substituted benzoxazoles and methods of use thereof |
KR20160090846A (en) | 2013-11-27 | 2016-08-01 | 제넨테크, 인크. | Substituted benzamides and methods of use thereof |
US10005724B2 (en) | 2014-07-07 | 2018-06-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
KR20180008761A (en) | 2015-05-22 | 2018-01-24 | 제넨테크, 인크. | Substituted benzamides and methods for their use |
EP3341353A1 (en) | 2015-08-27 | 2018-07-04 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
MX2018003828A (en) | 2015-09-28 | 2018-06-22 | Genentech Inc | Therapeutic compounds and methods of use thereof. |
JP2018535234A (en) | 2015-11-25 | 2018-11-29 | ジェネンテック, インコーポレイテッド | Substituted benzamides useful as sodium channel blockers |
WO2017172802A1 (en) | 2016-03-30 | 2017-10-05 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
CR20190236A (en) | 2016-10-17 | 2019-09-09 | Genentech Inc | Therapeutic compounds and methods of use thereof |
EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
CN112041313A (en) | 2018-02-26 | 2020-12-04 | 基因泰克公司 | Pyridine-sulfonamide compounds and their use against pain and related conditions |
JP2021519788A (en) | 2018-03-30 | 2021-08-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Condensation ring hydropyrido compound as a sodium channel inhibitor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE257480T1 (en) * | 1999-09-30 | 2004-01-15 | Pfizer Prod Inc | BICYCLIC PYRROLYLAMIDES AS GLYCOGEN PHOSPHORYLASE INHIBITORS |
CA2438492A1 (en) * | 2001-02-15 | 2002-08-22 | Pfizer Products Inc. | Proliferative activator receptor (ppar) compounds |
-
2004
- 2004-04-01 CN CNA2004800167362A patent/CN1805943A/en active Pending
- 2004-04-01 JP JP2006506478A patent/JP2006523671A/en active Pending
- 2004-04-01 WO PCT/IB2004/001159 patent/WO2004092145A1/en not_active Application Discontinuation
- 2004-04-01 KR KR1020057019591A patent/KR20060009846A/en not_active Application Discontinuation
- 2004-04-01 BR BRPI0409429-8A patent/BRPI0409429A/en not_active IP Right Cessation
- 2004-04-01 AP AP2005003418A patent/AP2005003418A0/en unknown
- 2004-04-01 EA EA200501462A patent/EA200501462A1/en unknown
- 2004-04-01 OA OA1200500283A patent/OA13157A/en unknown
- 2004-04-01 AU AU2004230316A patent/AU2004230316A1/en not_active Abandoned
- 2004-04-01 CA CA002521915A patent/CA2521915A1/en not_active Abandoned
- 2004-04-01 MX MXPA05010967A patent/MXPA05010967A/en not_active Application Discontinuation
- 2004-04-01 EP EP04725121A patent/EP1615899A1/en not_active Withdrawn
- 2004-04-12 PE PE2004000361A patent/PE20050415A1/en not_active Application Discontinuation
- 2004-04-13 UY UY28266A patent/UY28266A1/en not_active Application Discontinuation
- 2004-04-13 AR ARP040101236A patent/AR044514A1/en unknown
- 2004-04-14 PA PA20048600201A patent/PA8600201A1/en unknown
- 2004-04-14 NL NL1025946A patent/NL1025946C2/en not_active IP Right Cessation
- 2004-04-14 TW TW093110410A patent/TW200510353A/en unknown
- 2004-04-14 CL CL200400800A patent/CL2004000800A1/en unknown
-
2005
- 2005-09-15 IS IS8033A patent/IS8033A/en unknown
- 2005-10-14 MA MA28552A patent/MA27764A1/en unknown
- 2005-10-14 EC EC2005006105A patent/ECSP056105A/en unknown
- 2005-10-14 TN TNP2005000262A patent/TNSN05262A1/en unknown
- 2005-10-14 ZA ZA200508362A patent/ZA200508362B/en unknown
- 2005-11-14 NO NO20055370A patent/NO20055370L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR044514A1 (en) | 2005-09-14 |
NL1025946A1 (en) | 2004-10-18 |
EP1615899A1 (en) | 2006-01-18 |
PE20050415A1 (en) | 2005-06-13 |
UY28266A1 (en) | 2004-11-30 |
MA27764A1 (en) | 2006-02-01 |
OA13157A (en) | 2006-12-13 |
NO20055370D0 (en) | 2005-11-14 |
CA2521915A1 (en) | 2004-10-28 |
EA200501462A1 (en) | 2006-04-28 |
NL1025946C2 (en) | 2005-02-01 |
WO2004092145A1 (en) | 2004-10-28 |
BRPI0409429A (en) | 2006-04-18 |
CN1805943A (en) | 2006-07-19 |
AU2004230316A1 (en) | 2004-10-28 |
ZA200508362B (en) | 2006-11-29 |
KR20060009846A (en) | 2006-02-01 |
IS8033A (en) | 2005-09-15 |
NO20055370L (en) | 2006-01-12 |
PA8600201A1 (en) | 2005-02-04 |
MXPA05010967A (en) | 2005-11-28 |
TW200510353A (en) | 2005-03-16 |
JP2006523671A (en) | 2006-10-19 |
ECSP056105A (en) | 2006-03-01 |
CL2004000800A1 (en) | 2005-03-04 |
WO2004092145A8 (en) | 2005-05-12 |
AP2005003418A0 (en) | 2005-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN05262A1 (en) | ALPHA-SUBSTITUTED CARBOXYLIC ACIDS AS MODULATORS OF PPAR | |
MA27774A1 (en) | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | |
MA30932B1 (en) | SPIROCETONES AS INHIBITORS OF ACETYL-COA-CARBOXYLASE | |
MA27751A1 (en) | Substituted 4-phenyltetrahydroisoquinolines, process for producing these compounds, use of these compounds as medicaments and medicament containing such compounds | |
MA31373B1 (en) | Harmonic periodic amine compound. | |
MA28094A1 (en) | Bicyclic derivatives [3.1.0] as glycine transporter inhibitors | |
TNSN03130A1 (en) | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THEM, PHARMACEUTICAL USES THEREOF AND MATERIALS FOR THEIR SYNTHESIS | |
DE69920010D1 (en) | AROMATIC AMINE DERIVATIVES USED AS PHARMACEUTICAL AGENTS | |
MA27097A1 (en) | AZA-arylpiperazines | |
MA29692B1 (en) | XANTHINE DERIVATIVES AS SELECTIVE AGONISTS OF HM74A | |
MA27568A1 (en) | PYRROLOPYRIMIDINE DERIVATIVES | |
MA27908A1 (en) | THERAPEUTIC AGENTS USEFUL FOR THE TREATMENT OF PAIN | |
TNSN04156A1 (en) | SUBSTITUTED PYRIDINONES AS MODULATORS OF MAP-KINASE P38 | |
TNSN99006A1 (en) | 4- (2-CETO-1-BENZIMIDAZOLINYL) NOVEL PIPERIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
TNSN04164A1 (en) | ACC INHIBITORS | |
TNSN07349A1 (en) | N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | |
TNSN05104A1 (en) | THIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | |
MA31894B1 (en) | Organic compositions | |
TNSN00036A1 (en) | NOVEL OXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
MA29772B1 (en) | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION | |
TNSN05309A1 (en) | IMIDAZOLE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | |
TN2011000252A1 (en) | LACTAMS AS BETA-SECRETASE INHIBITORS | |
TNSN00232A1 (en) | NOVEL 2,4-DIAMINOPYRIMIDINE DERIVATIVES AND COMPOSITIONS CONTAINING THEM | |
TNSN03140A1 (en) | NEW SULFONIC ACID DERIVATIVES. | |
MA30532B1 (en) | CONDENSED TRICYCLIC SULFONAMIDES GAMMA SECRETASE INHIBITORS |